Zobrazeno 1 - 10
of 23
pro vyhledávání: ''
Autor:
Xi Chen, Hugh M. Davis, Rebecca Zhou, Jun Wang, Donald Heald, Weirong Wang, Xiling Jiang, Thomas J. Carpenter
Publikováno v:
mAbs. 10:876-889
T-cell redirecting bispecific antibodies (bsAbs) or antibody-derived agents that combine tumor antigen recognition with CD3-mediated T cell recruitment are highly potent tumor-killing molecules. Despite the tremendous progress achieved in the last de
Autor:
Feng Li, Zhidan Wu, Jin Chen, Huang Sijia, Zhang Boyan, Xinqiu Yuan, Jiannan Feng, Chunyang Jin, Xiaochuan Fan, Huifang Liu, Beifen Shen, Ye Pei
Publikováno v:
mAbs. 10:864-875
MBS301, a glyco-engineered bispecific anti-human epidermal growth factor receptor 2 (HER2) antibody with a typical IgG1 monoclonal antibody structure, was developed through dual-cell expression and in vitro assembling process. MBS301 consists of two
Publikováno v:
mAbs. :1-8
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. T-DM1 is composed of the humanized monoclonal antibody trastuzumab connected to a maytansine derivative cytotoxic drug, via a nonre
Autor:
Mingxuan Zhang, Huimin Li, Zachary Adam Yates, Helen J. McBride, Shawn Cao, Alla Polozova, Scott Kuhns, Jennifer Liu, Gwendolyn Maher, Neungseon Seo
Publikováno v:
mAbs
ABP 215 is a biosimilar product to bevacizumab. Bevacizumab acts by binding to vascular endothelial growth factor A, inhibiting endothelial cell proliferation and new blood vessel formation, thereby leading to tumor vasculature normalization. The ABP
Autor:
Aurélie Terrier, Emilie Jacque, Delphine Derache, Alexandre Fontayne, Aurélie Dehenne, Cécile Beghin, Alain Longue, Christophe De Romeuf, Gilles Dupont, Linda Baptista, Virginie Pochet-Beghin, Sami Chtourou, Anne-Sophie Dezetter, Nathalie Fournier, Lucie Verhaeghe
Publikováno v:
mAbs
Plasmacytoid dendritic cells (pDCs) play a central role for both innate and adaptive antiviral responses, as they direct immune responses through their unique ability to produce substantial concentrations of type I interferon (IFNs) upon viral encoun
Publikováno v:
mAbs
During the development of monoclonal antibodies (mAbs) and other therapeutic proteins, immunogenicity, in particular the induction of anti-drug antibodies (ADAs), is an important concern, and thus immunogenicity assessment is a requirement for their
Autor:
Janice M. Reichert, Hélène Kaplon
Publikováno v:
mAbs
The pace of antibody therapeutics development accelerated in 2017, and this faster pace is projected to continue through 2018. Notably, the annual number of antibody therapeutics granted a first approval in either the European Union (EU) or United St
Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study
Publikováno v:
mAbs. 10:143-158
Biosimilars are products that are similar in terms of quality, safety, and efficacy to an already licensed reference/ innovator product and are expected to offer improved affordability. The most significant source of reduction in the cost of developm
Autor:
Steven M Vicik, Morton Scheinberg, Uppuluri R K Rao, Brian Fitzpatrick, Julie O'Brien, Ena Singh, Mengtao Li, Ehab Mahgoub, Javier Coindreau, Brian Hassett, Gilberto Castañeda-Hernández
Publikováno v:
mAbs. 10:166-176
Fusion protein and monoclonal antibody-based tumor necrosis factor (TNF) inhibitors represent established treatment options for a range of inflammatory diseases. Regulatory authorities have outlined the structural characterization and clinical assess
Publikováno v:
mAbs. 9:1155-1168
Preferential interactions of weakly interacting formulation excipients govern their effect on the equilibrium and kinetics of several reactions of protein molecules in solution. Using vapor pressure osmometry, we characterized the preferential intera